FRA:5CV - Deutsche Boerse Ag - NL0015436031 - Common Stock - Currency: EUR
FRA:5CV (3/7/2025, 7:00:00 PM)
2.86
-0.07 (-2.52%)
The current stock price of 5CV.DE is 2.86 EUR. In the past month the price decreased by -18.8%. In the past year, price decreased by -7.44%.
Symbol | Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
4AB.DE | ABBVIE INC | 21.07 | 346.68B | ||
1ABBV.MI | ABBVIE INC | 20.82 | 342.48B | ||
AMG.DE | AMGEN INC | 16.43 | 161.21B | ||
1AMGN.MI | AMGEN INC | 15.84 | 160.89B | ||
1GILD.MI | GILEAD SCIENCES INC | 25.67 | 135.84B | ||
GIS.DE | GILEAD SCIENCES INC | 25.39 | 134.40B | ||
VX1.DE | VERTEX PHARMACEUTICALS INC | 1667.04 | 115.58B | ||
ARGX.BR | ARGENX SE | 253.61 | 33.75B | ||
22UA.DE | BIONTECH SE-ADR | N/A | 24.36B | ||
IDP.DE | BIOGEN INC | 9.25 | 20.54B | ||
1BIIB.MI | BIOGEN INC | 8.39 | 19.21B | ||
0QF.DE | MODERNA INC | N/A | 13.19B |
CureVac BV is a clinical-stage biopharmaceutical company, which engages in developing transformative medicines based on messenger ribonucleic acid (mRNA). The company is headquartered in Tuebingen, Baden-Wuerttemberg and currently employs 999 full-time employees. The company went IPO on 2020-08-14. Fueled by proprietary RNA technology platform combined with two decades of science and manufacturing, The Company is dedicated to creating novel treatments that enable the body to make its own prophylactic and therapeutic drugs.
CUREVAC NV
Friedrich-Miescher-Str. 15
Tuebingen BADEN-WUERTTEMBERG DE
Employees: 1086
Company Website: https://www.curevac.com/
Investor Relations: https://www.curevac.com/en/investor-relations/
Phone: 49707198830
The current stock price of 5CV.DE is 2.86 EUR. The price decreased by -2.52% in the last trading session.
The exchange symbol of CUREVAC NV is 5CV and it is listed on the Deutsche Boerse Ag exchange.
5CV.DE stock is listed on the Deutsche Boerse Ag exchange.
13 analysts have analysed 5CV.DE and the average price target is 7.48 EUR. This implies a price increase of 161.46% is expected in the next year compared to the current price of 2.86. Check the CUREVAC NV stock analysts ratings, price target forecast and up-and down grades for more detailed information.
CUREVAC NV (5CV.DE) has a market capitalization of 641.61M EUR. This makes 5CV.DE a Small Cap stock.
CUREVAC NV (5CV.DE) currently has 1086 employees.
CUREVAC NV (5CV.DE) has a support level at 2.85 and a resistance level at 3.61. Check the full technical report for a detailed analysis of 5CV.DE support and resistance levels.
The Revenue of CUREVAC NV (5CV.DE) is expected to grow by 700.96% in the next year. Check the estimates tab for more information on the 5CV.DE EPS, Sales, EBIT and EBITDA future analyst estimates.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
5CV.DE does not pay a dividend.
CUREVAC NV (5CV.DE) will report earnings on 2025-04-22, after the market close.
The PE ratio for CUREVAC NV (5CV.DE) is 5.96. This is based on the reported non-GAAP earnings per share of 0.48 and the current share price of 2.86 EUR. Check the full fundamental report for a full analysis of the valuation metrics for 5CV.DE.
ChartMill assigns a technical rating of 1 / 10 to 5CV.DE. When comparing the yearly performance of all stocks, 5CV.DE is a bad performer in the overall market: 82.1% of all stocks are doing better.
ChartMill assigns a fundamental rating of 6 / 10 to 5CV.DE. While 5CV.DE has a great health rating, its profitability is only average at the moment.
Over the last trailing twelve months 5CV.DE reported a non-GAAP Earnings per Share(EPS) of 0.48. The EPS increased by 134.53% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | 19.93% | ||
ROA | 12.68% | ||
ROE | 14.94% | ||
Debt/Equity | 0.05 |
ChartMill assigns a Buy % Consensus number of 78% to 5CV.DE. The Buy consensus is the average rating of analysts ratings from 13 analysts.
For the next year, analysts expect an EPS growth of 164.54% and a revenue growth 700.96% for 5CV.DE